StockNews.AI
CNSP
StockNews.AI
56 days

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

1. CNS Pharmaceuticals featured Dr. Erin Dunbar on Virtual Investor KOL Connect. 2. Discussion focused on Glioblastoma Multiforme and CNSP’s product TPI 287. 3. TPI 287 shows potential for treating brain tumors and has good safety profile. 4. Over 350 patients have been tested with TPI 287 in clinical trials. 5. Positive early efficacy data suggests TPI 287 crosses the blood-brain barrier.

6m saved
Insight
Article

FAQ

Why Bullish?

TPI 287's promising safety and efficacy can enhance investor confidence, similar to others like Zymeworks that had successful innovations leading to stock price increases. The clear focus on Glioblastoma, a high-need area, strengthens this perspective.

How important is it?

The company’s advancements in cancer treatment present a substantial potential for revenue generation, which influences investor sentiment strongly. The coverage by KOLs is also highly regarded.

Why Long Term?

Long-term value hinges on successful trials and potential FDA approval, akin to past biotech successes that saw improved fortunes over extended timelines.

Related Companies

ZymeworksAmgenNovartis
Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, who specializes in the comprehensive care of brain and spine tumor patients who are battling both primary and metastatic tumors.As part of the segment, Dr. Dunbar discussed the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma's lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.The Virtual Investor KOL Connect segment featuring CNS Pharma is now available here.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.Forward-Looking StatementsSome of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.CONTACTS:Investor Relations ContactJTC Team, LLCJenene Thomas908.824.0775[email protected]SOURCE: CNS Pharmaceuticals, Inc.

Related News